Ostia Sciences Inc. Completes $1.46M Seed Round to Develop Microbiome Therapeutics Platform.

The company receives additional non-dilutive funding from Natural Products Canada.

TORONTO--(BUSINESS WIRE)--Ostia Sciences Inc., a microbiome therapeutics company developing next-generation probiotics, today announced the successful close of its seed financing round, raising CAD $1.46 million as of December 31, 2024.

In addition to private investment, Ostia secured over $393,000 in non-dilutive grants, including $350,000 from Natural Products Canada (NPC) through its Proof-of-Concept (POC) program.

The NPC POC funding will help advance Ostia’s planned clinical trials, focusing on natural solutions for widespread conditions like gingivitis, halitosis, and treatment-related oral complications of head and neck cancer patients.

“Our progress reflects both strong investor confidence and essential support from Canadian innovation programs, enabling the commercialization of natural health solutions and helping millions of patients worldwide,” said Dr. Abdelahhad Barbour, CEO of Ostia Sciences. “We now have the resources to optimize our manufacturing processes and move SALI-10 toward clinical validation.”

With full ownership of its IP portfolio, an expanding team of advisors, and a robust discovery pipeline, Ostia Sciences is positioning itself as a leader in microbiome-based biotherapeutics.

“We’re building more than just a product, we’re creating a platform for targeted, microbiome-driven drug development,” said Dr. Michael Glogauer, Chief Scientific Officer. “This funding brings us one step closer to transforming how we treat oral and respiratory diseases.”